People: Progenics Pharmaceuticals, Inc. (PGNX.O)

PGNX.O on Consolidated Issue listed on NASDAQ Global Market

4.51USD
9 Feb 2010
Price Change (% chg)

$0.04 (+0.89%)
Prev Close
$4.51
Open
--
Day's High
$4.52
Day's Low
$4.36
Volume
67,092
Avg. Vol
108,758
52-wk High
$9.11
52-wk Low
$3.53

view people for:

Summary

Name Age Since Current Position
Briner, Kurt 65 2008 Chairman of the Board
Maddon, Paul 49 2004 Chief Executive Officer, Chief Science Officer, Director
Baker, Mark 54 2009 President, Director
McKinney, Robert 52 2006 Chief Financial Officer, Senior Vice President - Finance & Operations, Treasurer
Israel, Robert 52 2002 Senior Vice President - Medical Affairs
Boyd, Thomas 57 2005 Senior Vice President - Product Development
Krawiec, Richard 61 2006 Vice President - Corporate Affairs
Ray, Nitya 56 2004 Vice President - Manufacturing
Osorio, Benedict 52 2005 Vice President - Quality
Capone, Walter 44 2007 Vice President - Commercial Development and Operations
Assumma, Ann 55 Vice President - Regulatory Affairs
Ramakrishna, Tage 34 2008 Vice President - Clinical Research
Olson, William 46 2001 Vice President - Research & Development
Baker, Charles 76 1994 Director
Dalton, Mark 58 1990 Director
Goff, Stephen 57 1993 Director
Scheinberg, David 53 1996 Director
Williams, Nicole 65 2007 Director
Crowley, Peter 50 2009 Director
» Insider Trading

Biographies

Name Description
Briner, Kurt Mr. Kurt W. Briner is the Chairman of Progenics Pharmaceuticals, Inc. Mr. Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A, a position he held from 1988 until his retirement in 2000. He has 35 years of experience in the pharmaceutical industry, and is a director of Novo Nordisk Danmark and Galenica S.A., European-based pharmaceutical companies. He attended Humanistisches Gymnasium in Basel and Ecole de Commerce in Basel and Lausanne.
Maddon, Paul Dr. Paul J. Maddon, M.D., Ph.D. is Chief Executive Officer, Chief Science Officer, Director of Progenics Pharmaceuticals, Inc. He is founder and has served in various capacities since inception, including Chairman of the Board of Directors, Chief Executive Officer, President and Chief Science Officer. From 1981 to 1988, Dr. Maddon performed research at the Howard Hughes Medical Institute at Columbia University in the laboratory of Dr. Richard Axel. Dr. Maddon serves on several scientific review committees of the National Institutes of Health and on the Executive Committee of the Rockefeller University Council. He received a B.A. in biochemistry and mathematics, an M.D. and a Ph.D. in biochemistry and molecular biophysics from Columbia University. Dr. Maddon also serves as a trustee of Columbia.
Baker, Mark Mr. Mark R. Baker, J.D. has been appointed as President, Director of Progenics Pharmaceuticals, Inc. He served as Executive Vice President, General Counsel, Secretary of Progenics Pharmaceuticals, Inc. He Executive Vice President-Corporate, joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of ContiGroup Companies, Inc. (formerly Continental Grain Company) a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm, Dewey Ballantine. Mr. Baker was awarded an A.B. degree from Columbia College and a Juris Doctor from the Columbia University School of Law.
McKinney, Robert Mr. Robert A. McKinney, CPA is Chief Financial Officer, Senior Vice President - Finance & Operations, Treasurer of Progenics Pharmaceuticals, Inc. He has been Chief Financial Officer since 2005. Mr. McKinney joined the company in 1992 and currently serves as Senior Vice President Finance & Operations and Treasurer. Early in his career, he was an audit supervisor at Coopers & Lybrand LLP. Mr. McKinney studied finance at the University of Michigan, received a B.B.A. in accounting from Western Connecticut State University, and is a Certified Public Accountant.
Israel, Robert Mr. Robert J. Israel, M.D. is Senior Vice President, Medical Affairs of Progenics Pharmaceuticals, Inc. Before joining Progenics, he held oncology positions at Sandoz Pharmaceuticals Corporation and Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania, and completed an oncology fellowship at Sloan-Kettering Institute for Cancer Research. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.
Boyd, Thomas Mr. Thomas A. Boyd, Ph.D. is Senior Vice President, Product Development of Progenics Pharmaceuticals, Inc. From 1996 through 2000, Dr. Boyd was Associate Director, R & D Project Management at Boehringer Ingelheim Pharmaceuticals, Inc. and before that held various positions with Wyeth-Ayerst Research and Alteon, Inc. He received his Ph.D. from Brown University in physiology and biophysics and an A.B. degree from Cornell University’s College of Arts and Sciences.
Krawiec, Richard Dr. Richard W. Krawiec, Ph.D. is Vice President, Corporate Affairs of Progenics Pharmaceuticals, Inc. Prior to joining the company, Dr. Krawiec served in similar capacities at Cytogen Corporation, La Jolla Pharmaceuticals, Inc., Amylin Pharmaceuticals, Inc. and IDEC Pharmaceuticals, Inc. Dr. Krawiec was founder and Editor-In-Chief of Biotechnology Week magazine and founder and Managing Editor of Biotechnology Newswatch. He received a B.S. in biology from Boston University and a Ph.D. in biological sciences from the University of Rhode Island.
Ray, Nitya Dr. Nitya G. Ray, Ph.D. is Senior Vice President, Manufacturing of Progenics Pharmaceuticals, Inc. Prior to joining Progenics, Dr. Ray served as Director of Bioprocess Development at Ortec International from 1997 to 2001. From 1993 to 1997, Dr. Ray held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP Manufacturing and Process Development, ultimately as Research Leader, Biopharmaceuticals. From 1985 to 1993 he developed process technology for biopharmaceutical manufacturing at Verax Corporation. Dr. Ray received an M.S. and Ph.D. in chemical and biochemical engineering from Rutgers University and a B.S. in chemical engineering from Jadavpur University, India.
Osorio, Benedict Mr. Benedict Osorio, M.B.A. is Senior Vice President, Quality of Progenics Pharmaceuticals, Inc. He has almost three decades of experience in pharmaceutical quality control and quality assurance, including service as Director and Senior Director at Forest Laboratories from 2001 to 2005. From 1984 to 2001, Mr. Osorio held positions of increasing responsibility with The PF Laboratories (a subsidiary of Purdue Pharma), ultimately as Executive Director, Quality Assurance. From 1979 to 1984, he was an analytical chemist with Berlex Laboratories. He earned both an M.B.A. and an M.S. in chemistry from Seton Hall University and a B.S. in forensic science from John Jay College of Criminal Justice. Mr. Osorio is a Certified Quality Engineer and Quality Auditor recognized by the American Society for Quality.
Capone, Walter Mr. Walter M. Capone, M.B.A. is Vice President - Commercial Development and Operations of Progenics Pharmaceuticals, Inc. Mr. Capone was employed by Trimeris, Inc. from 2002 to 2007 as Senior Vice President of Commercial Operations managing the FUZEON® and fusion inhibitor commercial collaboration with Hoffmann LaRoche. He has 19 years of U.S. and international commercial experience in the pharmaceutical and biotechnology industries, having held vice president and director-level positions in marketing, sales management and commercial development in the U.S. and Europe for companies including Wyeth, Bristol-Myers Squibb and Triangle Pharmaceuticals, Inc. Mr. Capone earned his M.B.A. in finance and international business from Columbia University School of Business, and an undergraduate degree in international relations from Brown University.
Assumma, Ann Ms. Ann Marie Assumma, M.S. is Vice President, Regulatory Affairs of Progenics Pharmaceuticals, Inc. She has over 30 years of experience in the pharmaceutical industry and regulatory affairs at companies including Dov Pharmaceuticals, Emisphere Technologies, Bayer and American Cyanamid. Ms. Assumma earned her M.S. in pharmacology from New York Medical College and a B.S. in biology from Fordham University.
Ramakrishna, Tage Dr. Tage Ramakrishna, M.D. is Vice President, Clinical Research of Progenics Pharmaceuticals, Inc. Prior to joining the company, Dr. Ramakrishna worked for Altana Pharma, where he served from 2003 to 2007, most recently as Corporate Vice President of International Drug Safety and Medical Affairs. Prior thereto, Dr. Ramakrishna worked as Medical Director for Insmed Inc. He received an M.D. from Karol Marcinkowski University in Poznan, Poland and a B.A. in biology from Rutgers University.
Olson, William Dr. William C. Olson, Ph.D. is Senior Vice President, Research & Development of Progenics Pharmaceuticals, Inc. From 1989 to 1994, Dr. Olson was a scientist at Johnson & Johnson and MicroGeneSys, Inc., a biotechnology company. Dr. Olson has served on scientific review committees of the National Institutes of Health and has co-authored more than 40 articles for peer-reviewed scientific journals. Dr. Olson received a Ph.D. from the Massachusetts Institute of Technology and a B.S. from the University of North Dakota, both in chemical engineering.
Baker, Charles Mr. Charles A. Baker, J.D. is Director of Progenics Pharmaceuticals, Inc. He is a business advisor to biotechnology companies. He is the former Chairman, President and Chief Executive Officer of The Liposome Company, Inc., a biotechnology company located in Princeton, New Jersey, a position he held from 1989 until the sale of the company in 2000. Mr. Baker has 46 years of pharmaceutical industry experience and has held senior management positions at Pfizer, Abbott Laboratories and Squibb Corporation. He is a director of Regeneron Pharmaceuticals, Inc., a biotechnology company. Mr. Baker received a B.A. from Swarthmore College and a J.D. from Columbia University.
Dalton, Mark Mr. Mark F. Dalton is Director of Progenics Pharmaceuticals, Inc. He has been the President and a director of Tudor Investment Corporation, an investment advisory company, and its affiliates since 1988, and President and Vice Chairman since 2005. From 1979 to 1988, he served in various senior management positions, including Chief Financial Officer, at Kidder, Peabody & Co. Incorporated. He is a director of several private companies. Mr. Dalton received a B.A. from Denison University and a J.D. from Vanderbilt University Law School.
Goff, Stephen Dr. Stephen P. Goff, Ph.D. is Director of Progenics Pharmaceuticals, Inc. He has been the Higgins Professor in the Departments of Biochemistry and Microbiology at Columbia University, has been a scientific advisor to us since 1988. He received an A.B. in biophysics from Amherst College and a Ph.D. in biochemistry from Stanford University. Dr. Goff performed post-doctoral research at the Massachusetts Institute of Technology in the laboratory of Dr. David Baltimore.
Scheinberg, David Mr. David A. Scheinberg, M.D., Ph.D. is Director of Progenics Pharmaceuticals, Inc. He has been a scientific advisor to the company since 1994. Dr. Scheinberg has been associated with the Sloan-Kettering Institute for Cancer Research since 1986, where he is the Vincent Astor Chair and Member, Leukemia Service; Chairman, Molecular Pharmacology and Chemistry Program; Chairman, Experimental Therapeutics Center; and Head, Laboratory of Hematopoietic Cancer Immunochemistry. He also holds the positions of Professor of Medicine and of Pharmacology, Weill-Cornell Medical College. He received a B.A. from Cornell University and a M.D. and a Ph.D. in pharmacology and experimental therapeutics from The Johns Hopkins University School of Medicine.
Williams, Nicole Ms. Nicole S. Williams, M.B.A. is Director of Progenics Pharmaceuticals, Inc., since 20047. after retiring in 2006 as Chief Financial Officer of Abraxis Bioscience Inc., a biopharmaceutical company, and President of its Abraxis Pharmaceutical Products division, positions she assumed upon the 2006 merger of American Pharmaceutical Partners, Inc. and American Bioscience Inc. From 2002 to 2006, Ms. Williams was the Executive Vice President and Chief Financial Officer of American Pharmaceutical Partners, as well as President from 2005. Ms. Williams is President of the Nicklin Capital Group, Inc., a firm she founded in 1999 to invest in and provide consulting to early-stage technology companies in the Midwest. She is a director of Orchid Cellmark, Inc., a DNA identity testing service company and Intercept Pharmaceuticals, Inc., a privately-held biotechnology company. Ms. Williams received her Demi-License en Science Politique from the University of Geneva, Switzerland, her License en Science Politique from the Graduate Institute of International Affairs, University of Geneva, Switzerland and her M.B.A. from the Graduate School of Business, University of Chicago.
Crowley, Peter Mr. Peter J. Crowley is Directors of Progenics Pharmaceuticals, Inc. Mr. Crowley retired in 2008 as Manager Director of the Healthcare Investment Banking group at Oppenheimer & Company (formerly CIBC World Markets), which he headed since 1995, with responsibility for public and private financing and advisory services for biotechnology, pharmaceutical, medical device and healthcare services companies. Mr. Crowley serves on the board of directors of the New York Eye and Ear Infirmary, the Cancer Research Institute, the Foundation Fighting Blindness, the Glaucoma Foundation and Rye Country Day School. He is also a board member at Jurlique plc, a skin care company, and Napastyle, a specialty food and furnishings company. Mr. Crowley holds an M.B.A. in finance from Columbia University Graduate School of Business and a B.S. in economics from Harvard University.

Options Compensation

Name Options Value
Briner, Kurt 0 0
Maddon, Paul 1,688,775 24,746,750
Baker, Mark 50,000 249,500
McKinney, Robert 218,500 2,662,923
Israel, Robert 239,000 3,199,729
Boyd, Thomas 16,000 135,272
Krawiec, Richard 0 0
Ray, Nitya 0 0
Osorio, Benedict 0 0
Capone, Walter 0 0
Assumma, Ann 0 0
Ramakrishna, Tage 0 0
Olson, William 0 0
Baker, Charles 0 0
Dalton, Mark 0 0
Goff, Stephen 0 0
Scheinberg, David 0 0
Williams, Nicole 0 0
Crowley, Peter 0 0

Insider Trading

Name Shares Traded Price
MCKINNEY ROBERT A 2,864 $4.45
BOYD THOMAS A 2,864 $4.45
ISRAEL ROBERT J 3,843 $4.45
BAKER MARK ROBERT 4,720 $3.78
MCKINNEY ROBERT A 3,147 $3.78
OLSON WILLIAM C 2,989 $3.78
BOYD THOMAS A 3,147 $3.78
ISRAEL ROBERT J 4,223 $3.78
OLSON WILLIAM C 2,720 $4.45
BAKER MARK ROBERT 4,295 $4.45
MADDON PAUL J 18,500 $4.88
MCKINNEY ROBERT A 2,666 $4.26
BAKER MARK ROBERT 3,639 $5.01
BOYD THOMAS A 2,666 $4.26
ISRAEL ROBERT J 3,578 $4.26
OLSON WILLIAM C 2,533 $4.26
BAKER MARK ROBERT 3,999 $4.26
MCKINNEY ROBERT A 2,426 $5.01
BOYD THOMAS A 2,426 $5.01
ISRAEL ROBERT J 3,256 $5.01
OLSON WILLIAM C 2,305 $5.01
BAKER MARK ROBERT 13,207 $5.33
BOYD THOMAS A 7,738 $5.33
OLSON WILLIAM C 6,461 $5.33
MCKINNEY ROBERT A 7,738 $5.33
» Full list on Insider Trading
view people for: